The FDA has approved Ameluz (aminolevulinic acid hydrochloride; Biofrontera) gel, for the treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp.
Indications: Ameluz gel is a porphyrin precursor, which is used in combination with photodynamic therapy using the BF-RhodoLED lamp. It is indicated for lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Dosage/administration: Each gram of Ameluz gel 10% contains 100 mg of aminolevulinic acid hydrochloride (equivalent to 78 mg of aminolevulinic acid). Ameluz gel is to be administered by a health care provider and is for topical use only. Photodynamic therapy with Ameluz involves preparation of lesions, application of the product, and occlusion and illumination with BF-RhodoLED. Lesions that have not completely resolved 3 months after the initial treatment should be retreated.
Adverse reactions: The most common adverse reactions (≥10%) were application site erythema, pain/burning, irritation, edema, pruritis, exfoliation, scab, induration, and vesicles.
Citation: Biofrontera announces US FDA approval of Ameluz and activating BF-RhodoLED device for treatment of actinic keratosis. [news release]. Leverkusen, Germany: Biofrontera; May 11, 2016: www.biofrontera.com. Accessed May 11, 2016.
This Week's Must Reads
Opioids and the Dermatology Medicare Population, JAMA Dermatology; ePub 2018 Feb 7; Cao, et al
Significant Care Costs Associated with Cellulitis, J Am Acad Dermatol; ePub 2018 Feb 7; St. John, et al
An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al
Underlying Disease Impact on Pyoderma Gangrenosum, J Am Acad Dermatol; ePub 2018 Feb 10; Kaffenberger, et al
FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8
Must Reads in Actinic Keratosis
Red Light ALA PDT Well Tolerated in AK Treatment, Photomed Laser Surg; ePub 2017 Dec 11; Paragh, et al
Cost of Managing AK Varies by Region, JAMA Dermatol; ePub 2017 Mar 1; Kirby, et al
Physician Wording Role in Seeking AK Treatment, JAMA Dermatol; ePub 2017 Jan 18; Berry, Butt, et al
Acantholysis in SCC Not Considered High Risk, J Am Acad Dermatol; ePub 2016 Nov 23; Ogawa, et al
Prevalence of Nonmelanoma Skin Cancers High in VHA, Dermatol Surg; ePub 2016 Jul 25; Yoon, Phibbs, et al